Biomarker Identification for Alzheimer's Disease

(DIAN Trial)

Recruiting at 25 trial locations

Overseen By Alisha Daniels, MD,MHA

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Washington University School of Medicine

Disqualifiers: Under 18, Nursing home care, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

700 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to identify biomarkers, which are biological signs, that might predict Alzheimer's disease in individuals with a genetic mutation linked to the condition. It targets those at risk due to a parent's Alzheimer's diagnosis and who exhibit little to no cognitive impairment. Participants must be adults who have not yet shown symptoms and must have two non-sibling contacts to assist with the study.

As an unphased trial, this study offers participants the opportunity to contribute to groundbreaking research that could lead to early detection methods for Alzheimer's.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on understanding the early stages of Alzheimer's in individuals with a genetic predisposition, rather than testing a specific treatment. Unlike current options that primarily address symptoms of Alzheimer's after they've appeared, this study aims to uncover insights into how the disease develops over time in those who are more likely to inherit it. By monitoring people who carry genetic mutations linked to Alzheimer's, scientists hope to identify potential targets for future therapies that could delay or even prevent the onset of symptoms. This could pave the way for groundbreaking preventive strategies, offering hope for at-risk families.

Who Is on the Research Team?

Eric McDade, DO

Principal Investigator

Washington University School of Medicine

Alisha Daniels, MD,MHA

Principal Investigator

[phone]

Are You a Good Fit for This Trial?

Inclusion Criteria

Written informed consent obtained from participant and collateral source prior to any study-related procedures.

Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.

Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Recruitment and Baseline Assessment

Recruitment of new asymptomatic participants and baseline assessment of clinical, cognitive, imaging, and fluid biomarkers

Year 1

1 visit every 2 years

Ongoing Assessment

Participants are assessed every 2 years with the DIAN protocol to monitor changes in biomarkers and clinical status

Ongoing

1 visit every 2 years

Follow-up

Participants are monitored for safety and effectiveness after initial assessments

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• No treatment

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials

2,027

Recruited

2,353,000+

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+